Johnson & Johnson (NYSE:JNJ) Shares Bought by Applied Finance Capital Management LLC

Key Points

• Applied Finance Capital Management LLC increased its holdings in Johnson & Johnson by 12.6% in Q1, now owning 32,185 shares valued at approximately $5.34 million.
• Multiple institutional investors, including Brighton Jones LLC and Hudson Value Partners LLC, have also raised their stakes in Johnson & Johnson during the fourth quarter, contributing to a total institutional ownership of 69.55%.
• Analysts have a consensus rating of "Moderate Buy" for Johnson & Johnson, with recent price targets ranging from $162.00 to $185.00.

Applied Finance Capital Management LLC boosted its holdings in Johnson & Johnson (NYSE:JNJ - Free Report) by 12.6% in the first quarter, according to its most recent filing with the SEC. The institutional investor owned 32,185 shares of the company's stock after buying an additional 3,594 shares during the period. Applied Finance Capital Management LLC's holdings in Johnson & Johnson were worth $5,338,000 as of its most recent SEC filing.

Other institutional investors have also bought and sold shares of the company. WealthTrak Capital Management LLC purchased a new position in shares of Johnson & Johnson during the fourth quarter valued at about $26,000. Conquis Financial LLC purchased a new position in Johnson & Johnson in the fourth quarter worth about $33,000. Bernard Wealth Management Corp. purchased a new position in Johnson & Johnson in the fourth quarter worth about $36,000. Highline Wealth Partners LLC grew its position in Johnson & Johnson by 51.8% in the first quarter. Highline Wealth Partners LLC now owns 252 shares of the company's stock worth $42,000 after acquiring an additional 86 shares in the last quarter. Finally, von Borstel & Associates Inc. purchased a new position in Johnson & Johnson in the first quarter worth about $49,000. Hedge funds and other institutional investors own 69.55% of the company's stock.

Analyst Upgrades and Downgrades

Several research analysts recently commented on the company. UBS Group lifted their price target on Johnson & Johnson from $180.00 to $190.00 and gave the stock a "buy" rating in a research report on Thursday, July 17th. Sanford C. Bernstein reiterated a "market perform" rating on shares of Johnson & Johnson in a research report on Wednesday, April 16th. Raymond James Financial dropped their price target on Johnson & Johnson from $165.00 to $162.00 and set an "outperform" rating for the company in a research report on Monday, April 14th. Erste Group Bank upgraded Johnson & Johnson from a "hold" rating to a "buy" rating in a research report on Wednesday, July 23rd. Finally, Royal Bank Of Canada raised their price objective on shares of Johnson & Johnson from $181.00 to $185.00 and gave the stock an "outperform" rating in a research note on Thursday, July 17th. Nine investment analysts have rated the stock with a hold rating, ten have given a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $174.50.

Johnson & Johnson Trading Down 0.1%

Shares of Johnson & Johnson stock traded down $0.15 on Wednesday, hitting $167.96. 1,920,906 shares of the company traded hands, compared to its average volume of 9,034,078. The stock's 50 day moving average price is $156.65 and its 200-day moving average price is $156.22. The company has a current ratio of 1.01, a quick ratio of 0.76 and a debt-to-equity ratio of 0.50. Johnson & Johnson has a 52 week low of $140.68 and a 52 week high of $169.99. The company has a market cap of $404.13 billion, a PE ratio of 17.97, a PEG ratio of 2.12 and a beta of 0.41.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its quarterly earnings data on Wednesday, July 16th. The company reported $2.77 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.68 by $0.09. The company had revenue of $23.74 billion for the quarter, compared to analyst estimates of $22.85 billion. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. Johnson & Johnson's revenue was up 5.8% compared to the same quarter last year. During the same period last year, the company posted $2.82 earnings per share. Equities research analysts predict that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 9th. Shareholders of record on Tuesday, August 26th will be issued a $1.30 dividend. This represents a $5.20 annualized dividend and a yield of 3.10%. The ex-dividend date is Tuesday, August 26th. Johnson & Johnson's dividend payout ratio is currently 55.61%.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.